Table 3.
Relation between NSCLC patients’ characteristics and miR‐635 expression
| Factors | Tissue miR‐635 (n = 60) | P | |
|---|---|---|---|
| Low (n = 38) | High( n = 22) | ||
| Age (y) | |||
| ≤65 | 15 | 10 | .651 |
| >65 | 23 | 12 | |
| Gender | |||
| Male | 16 | 11 | .554 |
| Female | 22 | 11 | |
| Smoking status | |||
| Nonsmoker | 20 | 12 | .886 |
| Ever‐smoker | 18 | 10 | |
| Histologic type | |||
| Squamous | 26 | 9 | .037 |
| Nonsquamous | 12 | 13 | |
| T status | |||
| T1‐2 | 19 | 12 | .734 |
| T3‐4 | 19 | 10 | |
| N status | |||
| N0 | 17 | 9 | .773 |
| N1‐3 | 21 | 13 | |
| Stage | |||
| Ⅰ‐Ⅱ | 18 | 12 | .592 |
| Ⅲ | 20 | 10 | |
| Differentiation | |||
| Well moderate | 16 | 9 | .928 |
| Poor | 22 | 13 | |
| EGFR mutation status | |||
| Mutated | 17 | 13 | .284 |
| Wild‐type | 21 | 9 | |
Abbreviations: EGFR, epidermal growth factor receptor; NSCLC, non‐small cell lung cancer.